belzutifan
merck
['rcc,(-irccs),(-srcc),(-urcc)', 'belzutifan']
dr. discusses results of litespark presente by trial with belzutifan in sporadic mrcc with longer follow up, disease control rate of 80%. #asco22 
Medical oncologist at @BPorgbr. Former fellow of GU oncology @DanaFarber @Harvard @MOCbrasil. #GUcancer